Multiple Myeloma
Conditions
Interventions
Electroacupuncture Group:Electroacupuncture
Control Group:Standard care
Sponsors
Guangzhou hospital of integrated Chinese and Western medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: a.Diagnosed with multiple myeloma, fulfilling the European Society for Medical Oncology (ESMO) diagnostic criteria. b.Scheduled to receive a bortezomib-containing regimen for at least 2 cycles. c. Absence of clinically significant peripheral neuropathy at enrollment (NCI CTCAE v6.0 grade 0). d. Aged between 18 and 80 years, regardless of gender, with an estimated life expectancy of = 6 months. e.Meet the above criteria, voluntarily agree to participate in the study protocol, and provide written informed consent
Exclusion criteria
Exclusion criteria: a.Presence of severe cognitive impairment that hinders communication or accurate self-assessment. b.Presence of peripheral neuropathy attributable to other causes(e.g.,nutritional deficiencies,alcoholism,severe diabetes mellitus). c. Comorbid with severe primary diseases of the cardiovascular,cerebrovascular,hepatic,renal,or hematopoietic systems. d. Pregnant or lactating women. e. History of other concurrent malignant tumors. f. Contraindications to electroacupuncture (e.g.,local skin infection at needling sites,presence of a cardiac pacemaker). g. Platelets <50×10^9/L, white blood cells <3.0×10^9/L before treatment. h.Individuals with needle phobia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Bortezomib-Induced Peripheral Neuropathy (BIPN); | — |
Secondary
| Measure | Time frame |
|---|---|
| levels of inflammatory factors(IL-6 CRP);The score of European Organisation for Research and Treatment of Cancer - quality of life core questionnaire(QLQ-C30)/Chemotherapy-Induced Peripheral Neuropathy ( CIPN20);visual analogue scale, VAS; | — |
Countries
China
Contacts
Public ContactLi Yizhen
Guangzhou hospital of integrated Chinese and Western medicine
Outcome results
None listed